Semaglutide vs Tirzepatide vs Retatrutide vs Mazdutide vs Survodutide: GLP-1 Research Compounds Compared

If you follow metabolic research at all, you have watched the incretin-peptide field get crowded fast. A decade ago the conversation was essentially about one receptor. Today the literature spans single, dual, and triple receptor agonists, each engineered to engage a different combination of signaling pathways. For anyone sourcing reference material for laboratory work, the practical question is no longer "which peptide" but "which receptor profile" — because that profile is the single variable that defines what a given compound is studied to do in preclinical and in-vitro models. This tirzepatide vs semaglutide vs retatrutide comparison organizes the whole class by that one variable.

This guide compares the six most-referenced compounds in the GLP-1 research class — Semaglutide, Tirzepatide, Retatrutide, Mazdutide, Survodutide, and Cagrilintide — strictly by the receptor pharmacology reported in the published research design. Everything below is framed for laboratory and research use only. Nothing here is medical guidance, dosing information, or a claim about outcomes in humans. It is a map of mechanism, so a researcher can tell these molecules apart on paper.

First, the receptor vocabulary

Three receptors do most of the work in this class. Understanding what each one is studied for makes the whole comparison table readable at a glance.

• GLP-1 receptor (glucagon-like peptide-1). The foundational incretin target. In metabolic research models, GLP-1 receptor agonism is the most heavily characterized pathway in the entire class, studied in the context of glucose-dependent insulin signaling and energy-balance regulation.
• GIP receptor (glucose-dependent insulinotropic polypeptide). The second incretin receptor. Research interest centers on whether co-engaging GIP alongside GLP-1 produces effects in preclinical models that single-receptor agonism does not.
• Glucagon receptor. Distinct from the incretin receptors. In animal models, glucagon-receptor engagement is studied for its role in energy expenditure and hepatic metabolism — a different axis than the insulin-secretion story of GLP-1 and GIP.
• Amylin receptor. A separate signaling system entirely. Amylin analogs are studied alongside — not as — the incretin agonists, which is why Cagrilintide sits in its own row below.

The "single vs. dual vs. triple agonist" language you see everywhere simply counts how many of these receptors a given molecule is designed to engage. That count is the cleanest way to organize the class.

The comparison table: receptor pharmacology as studied

The table below summarizes each compound by the receptors it targets, its structural class, its CAS identifier, and the research programs most associated with it in the literature. Every row links to that compound's listing, where you can check current in-stock status and open its lot-level Certificate of Analysis (Janoshik / Freedom Diagnostics) — availability rotates as new lots land, so status is worth checking live.

Read down the "agonist class" column and the structure of the whole field appears: one single-receptor agonist, three different flavors of dual agonist, one triple agonist, and one amylin analog that plays a supporting role. That is the entire landscape in six rows.

Single agonist: Semaglutide, the reference point

Semaglutide is a 31-amino-acid GLP-1 receptor agonist carrying a fatty-acid side chain that extends its half-life. It is the most-characterized incretin peptide in the metabolic literature, which is exactly why researchers treat it as the baseline — the compound every newer molecule gets measured against in study design. The SUSTAIN and STEP research programs established its pharmacological profile in the published record.

For a lab building a comparison series, single-receptor agonism is the clean control condition: one pathway, well-documented, no confounding from a second or third receptor. If you are trying to isolate what GLP-1 signaling alone contributes in a model, this is the reference material you reach for.

Dual agonists: three different pairings

"Dual agonist" is not one thing. The three dual agonists in this class engage different second receptors, and that difference is the whole point of studying them separately.

Tirzepatide (GIP + GLP-1)

Tirzepatide is a 39-amino-acid peptide studied as a dual agonist of the GIP and GLP-1 receptors — the two incretin receptors. This is the "both incretins" pairing. The SURPASS and SURMOUNT research programs made it the most-referenced dual agonist in the literature. Because it engages two incretin pathways, it is the natural comparator when a study wants to ask whether adding GIP to GLP-1 changes anything in a preclinical model.

Survodutide (GLP-1 + glucagon)

Survodutide (BI-456906) pairs GLP-1 with the glucagon receptor instead of GIP. That swaps one incretin pathway for the energy-expenditure/hepatic axis that glucagon-receptor research explores. It is a different question than Tirzepatide asks — not "two incretins" but "one incretin plus glucagon." Less commercialized than the headline compounds, it is of growing interest in the literature as an alternative incretin/glucagon-axis tool.

Mazdutide (GLP-1 + glucagon)

Mazdutide (IBI362 / LY3305677) is also studied as a GLP-1/glucagon dual agonist, derived from the oxyntomodulin scaffold — a naturally occurring peptide that itself engages both GLP-1 and glucagon receptors. So Mazdutide and Survodutide share a receptor pairing on paper but come from different structural lineages, which is precisely the kind of distinction a Mazdutide-vs-Survodutide research series is designed to probe. Both live in the broader overseas catalog rather than the fast US in-stock line.

Triple agonist: Retatrutide, all three receptors

Retatrutide (LY3437943) is the most-discussed triple agonist in the class, a 39-amino-acid synthetic peptide studied as an agonist of GLP-1, GIP, and glucagon receptors simultaneously. It is the only compound in this comparison studied as an agonist of all three metabolic receptors at once, which is why it draws sustained attention from researchers characterizing next-generation incretin-class mechanisms in the Eli Lilly LY3437943 program.

Conceptually, Retatrutide is Tirzepatide's GIP+GLP-1 pairing plus the glucagon axis that Survodutide and Mazdutide add — the union of both dual-agonist strategies in a single molecule. That framing is the cleanest way to hold the whole class in your head: single, then two different ways to make a pair, then all three combined.

The amylin outlier: Cagrilintide

Cagrilintide belongs in this discussion but not in the agonist-count hierarchy, because it does not target the incretin or glucagon receptors at all. It is a long-acting 37-amino-acid amylin analog. In the research literature it is studied as a co-administered tool alongside Semaglutide — the CagriSema combination — to investigate what amylin signaling adds on top of GLP-1 agonism. If your comparison series is about receptor breadth, Cagrilintide is the reminder that the metabolic-peptide field extends beyond the incretin/glucagon axis into a separate signaling system entirely.

How to choose reference material for a comparison study

Reduced to mechanism, the selection logic is straightforward:

• Isolating GLP-1 alone? Semaglutide is the single-receptor reference point.
• Studying the two incretins together? Tirzepatide is the GIP+GLP-1 dual agonist.
• Adding the glucagon axis to GLP-1? Survodutide and Mazdutide are the two dual agonists to compare, and they differ by structural lineage.
• Engaging all three metabolic receptors? Retatrutide is the triple agonist.
• Reaching outside the incretin system? Cagrilintide brings the amylin pathway.

US in-stock reference compounds — Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide — ship on the fast line (typically 2–4 days) and can be reviewed in the in-stock research catalog. The broader set including Mazdutide and Survodutide lives in the full overseas catalog. Every listing carries its CAS number and a lot-level Certificate of Analysis, because for research material the receptor profile on paper only matters if the vial actually contains the labeled compound at documented purity. Checkout is a simple manual process (PayPal / Venmo / Bitcoin, with a discount for BTC).

A note on how these are supplied

All six compounds are supplied as lyophilized powder in research vials, reconstituted per the researcher's own laboratory protocol, and are intended for laboratory and research use only — not for human or animal consumption. These are supplied as research-grade reference materials, characterized by a lot-level Certificate of Analysis for identity and purity, and are described and intended solely for laboratory research. Nothing in this article should be read as guidance for use in humans.